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Nizar J. Bahlis, Christopher B. Brown, Andrew Daly, Peter Duggan, Michelle Geddes,
Diana Quinlan, Mary Lynn Savoie, Mona Shafey, Douglas A. Stewart, Jan Storek,
Maggie Yang, Nancy Zacarias, Ping Yue, Anthony M. Magliocco, James A. RussellIntravenous (i.v.) busulfan (Bu) administered once daily in myeloablative transplant regimens is convenient,
effective, and relatively well tolerated. Therapeutic drug monitoring is recommended as nonrelapse mortal-
ity increases when daily exposure, as determined by the area under the plasma concentration versus time
curve (AUC), exceeds 6000 mM$min.We describe sequential studies to achieve accurate prediction of treat-
ment doses of Bu based on the kinetics of a smaller test dose. A total of 335 patients with hematologic ma-
lignancies were given daily i.v. Bu 3.2 mg/kg  4 and fludarabine 50 mg/m2  5. Pharmacokinetic monitoring
was conducted for both the test dose and first treatment dose of Bu (day 25). Three different test dose
schedules were evaluated: 12 mg Bu administered over 20 minutes, 0.8 mg/kg over 3 hours, and 0.8 mg/
kg infused at 80 mg/h. The 3.2 mg/kg treatment doses were infused over a fixed time of 3 hours for the first
2 test dose trials and at a fixed rate of 80 mg/h for the final protocol. All test dose infusions were on day27.
In the first 2 schedules, Bu administered over a fixed time had significantly higher clearance for the test dose
compared with the treatment dose. However, when both the test and the treatment doses were adminis-
tered at the same infusion rate, clearance of the drug between the 2 dosing days was equivalent. Predicted
day25 AUC (AUC25) showed a high linear correlation (r
25 0.74) to the actual AUC25. The error of these
predictions was\20% in 98% of patients and\10% in 80%. In 24 individuals, the test dose predicted an AUC
.5500 mM$min; therefore, the first Bu treatment dose was reduced to a desired target AUC. All adjusted
doses fell within 20% of the targeted exposure. We conclude that a test dose strategy for therapeutic drug
monitoring of daily i.v. Bu is accurate if the test and treatment doses are infused at the same rate. This
approach allows targeting of therapeutic doses of Bu to desired levels and the potential for improved safety
and efficacy.
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Busulfan (Bu) is a bifunctional alkylating agent used
in conditioning regimens for hematopoietic stem cell
transplantation. An intravenous (i.v.) formulation haslberta Blood andMarrow Transplant Program, Foothills
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6/j.bbmt.2011.07.015been developed, leading to more predictable delivery
and probably improved clinical outcomes compared
with oral Bu [1-12]. Even after i.v. administration,
however, the exposure may vary by 3- to 4-fold. Phar-
macokinetic (PK) studies with both oral and i.v. Bu
have indicated that exposures above a critical level
are accompanied by unacceptably high toxicity and
consequent nonrelapse mortality [13,14]. Even within
a commonly accepted therapeutic range, there is
evidence that toxicity may increase with increasing
exposures [7]. Therapeutic drug monitoring of Bu PK
in individual patients with dose adjustment may there-
fore help to improve clinical outcomes [1]. One strat-
egy is to check the PK of an early treatment dose and
adjust subsequent doses if necessary [15]. The second
is to base any necessary adjustments on the PK of
a test dose given some time before the first treatment
dose [16,17]. We describe the results of sequential295
296 Biol Blood Marrow Transplant 18:295-301, 2012S. B. Kangarloo et al.studies to develop a reliable test dose regimen for
once-daily i.v. Bu.PATIENTS AND METHODS
Patients
The initial study included 99 patients with hema-
tologic disorders undergoing allogeneic hematopoi-
etic stem cell transplantation. The first 2 groups of
34 and 11 patients had different Bu test doses infused
over a fixed time. When the optimal strategy of fixed
rate infusion had been defined in the third group of
54 patients, a subsequent cohort of 236 patients was
used as a validation group and included 24 for whom
dose adjustments were made based on the test dose re-
sults. These patients had doses adjusted if predicted
exposures were .5500 mM$min. Initially, the adjust-
ment target in the first 3 patients was 5500 mM$min;
however, in subsequent patients, the desired target
was 5000 mM$min to allow for a 20% margin of error.
The 212 patients without dose adjustments were in-
cluded with the original 54 for a total of 266 patients
given the test dose at a fixed rate without dose adjust-
ment. Diagnoses and other details of the 4 groups are
recorded in Table 1.
All patients enrolled in the study provided in-
formed consent and met institutional guidelines for
transplant eligibility. The protocol and consent forms
were approved by the University of Calgary Health
Research Ethics Board.Test Dose and Treatment Regimen
With transplantation on day 0, all patients received
3.2 mg/kg Bu (based on the lower of actual or adjusted
ideal body weight) once-daily i.v. on days25 to22 in-Table 1. Diagnoses, Disease Stage, and Age Distribution of Each G
Group
Test Dose 12 mg
over 20 Minutes
Test Dose 0.8 mg/kg
over 3 Hours
Number 34 11
Patient age (yr),
median (range)
48 (18-65) 38 (19-66)
Male 22 (65%) 6 (55%)
Diagnosis # % # %
AML 14 42 5 45
ALL 2 6 2 18
CML
CLL 2 18
NHL 2 6
MM 6 18
HD 2 6 1 9
MDS 3 9 1 9
MF
Other 5 15
Phenytoin 34 100 11 100
AML indicates acute myelogenous leukemia/granulocytic sarcoma; ALL, acute
mia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MM,m
myelofibrosis.clusive, either as a 3-hour infusion or at an infusion
rate (IR) set at 80 mg/h. Fludarabine 50 mg/m2 i.v.
was given on days26 to22, inclusive. The first group
of 34 patients was given a test dose of 12 mg Bu infused
over 20 minutes, with the treatment dose infused over
3 hours. The second group of 11 patients received both
the test dose of 0.8 mg/kg Bu and the treatment doses
over 3 hours. The final 290 patients had a test dose of
0.8 mg/kg and all treatment doses infused at a fixed
rate of 80 mg/h. This rate was approximately the me-
dian IR of our historic cohort of patients given daily
i.v. Bu infused over 3 hours.
For the first 131 patients, phenytoinwas given from
day212 until day21. On the day of the first treatment
dose of Bu, the phenytoin dose was adjusted if the level
was outside a target range of 40 to 80 mmol/L. The final
204 patients received anticonvulsant therapy with lora-
zepam. The PK results of patients given different anti-
convulsants were combined because there was no
difference in the relationship of clearances between
test and treatmentdoses.Discontinuationof phenytoin,
when deemednecessary, was reported to thePK labora-
tory.No other drugswere routinely administered at the
time of the test dose. Routine prophylaxis for nausea
with granisitron was given during administration of
Bu treatment doses. Concomitant medication was
reviewed retrospectively when errors in the prediction
of treatment doses.20% were observed.Pharmacokinetic Analysis
PK samples were collected for both the test dose day
and the first treatment dose of Bu. Blood samples (5mL)
were collected in heparin tubes at the end of the Bu in-
fusion and 1, 3, 5, and 7 hours after the end of the Bu in-
fusion. Bu concentration in plasma was determined by
ultraviolet high-performance liquid chromatography,roup
Test Dose 0.8 mg/kg at
80 mg/h Nonadjusted
Test Dose 0.8 mg/kg
at 80 mg/h Adjusted
266 24
49 (18-66) 47 (19-61)
152 (57%) 13 (54%)
# % # %
117 44 11 46
42 16 7 29
13 5
18 7 3 13
21 8
3 5 1 4
24 9 2 8
14 5
15 5
84 32 2 8
lymphoblastic/biphenotypic leukemia; CML, chronic myelogenous leuke-
ultiple myeloma; HD, Hodgkin’s disease6CLL; MDS, myelodysplasia; MF,
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mate trihydrate as previously described [14]. Each pa-
tient sample set was extracted and quantified along
with its own Bu spiked plasma 5-point calibration set.
Intraday and interday coefficients of variation for the as-
say were \15%. The limit of detection and limit of
quantification were 0.01 mg/mL and 0.05 mg/mL, re-
spectively, and the assay was linear between 0.05 mg/
mL to 5.0 mg/mL.
PK data were analyzed by noncompartmental anal-
ysis using WinNonlin Professional version 5.0.1 soft-
ware (Pharsight Corp., Mountain View, CA). The
area under the plasma concentration versus time curve
(AUC) was calculated by the log-linear trapezoidal
rule from time zero to the last sampling time (AUClast).
The AUC from the last sampling time to infinity was
extrapolated by Clast/lz, where Clast and lz are the last
measured (nonzero) plasma Bu concentration and the
terminal slope on the natural logarithmic scale, respec-
tively. This extrapolated area was added to the AUClast
for the final AUC to infinity calculation (AUCN). The
percentage of the AUCN extrapolated was less than
10% for all patients. Total body clearance (Cl) was cal-
culated as:
Dose=AUCN:
PK data from the test dose were used to predict the
AUC for the first treatment day of Bu, Day 25
(AUC25) as: AUC25 5 (AUCtest  Dose25)/Dosetest,
whereDose25 was the intended 3.2-mg/kg dose before
adjustment and Dosetest was the 0.8 mg/kg test dose
administered on day 27. If the test dose predicted
the AUC25 to be above 5500 mM$min, Bu dose was re-
duced to target a desired AUC by:
New Adjusted dose

mg

5

Dosetest=AUCtest

Desired AUC 5 Test Dose ClearanceðCltestÞ
 Desired AUC:
Statistical Analysis
In each test dose regimen, Cltest was compared
with the respective paired day 25 treatment clearance
(Cl25) by the Student’s t test, paired, 2-tailed, level of
significance, P\ .05.Table 2. Summary of Doses and Infusion Rates during the 3 Test D
Group n
Test Dose
Dose
Infusion Rate
mg/h mg/h/k
1 34 12 (9-18) 44 (36-46) 0.53 (0.32-
2 11 59 (40-75) 20 (13-29) 0.25 (0.14-
3 266 56 (33-85) 73 (40-109) 0.95 (0.49-
Values given as median (range).Accuracy of test dose prediction was assessed by
the percent error calculation:
Predicted AUC25 by the test dose
2Confirmed AUC25

Confirmed AUC25
 100
Accuracy of dose adjustment was assessed by the
percent error calculation:

Adjusted Confirmed AUC252Target AUC25

Target AUC25
 100
Because accuracy was equally distributed between
underestimations and overestimations, absolute errors
were used to calculate the mean and 95% confidence
intervals (95% CI).
Percent coefficient of variation (% CV) was calcu-
lated by:
ðStandard deviation=MeanÞ  100
RESULTS
Busulfan Pharmacokinetics
Three different test dose regimens were com-
pared in 335 patients, including 24 dose-adjusted
patients, once the fixed IR protocol was validated
(Table 1). The range of Bu concentrations detected
was from 0.054 mg/mL to 4.81 mg/mL; hence, the
range was within the quantification limit and linear
range of the HPLC assay. Table 2 summarizes the
median dose and IRs of the 3 groups. There were ap-
proximately 2-fold and 4-fold differences in infusion
rates between the test dose and treatment dose in
groups 1 and 2, respectively, if the IR was not con-
trolled, that is, when Bu was infused over a set infu-
sion time. The trend to increasing IR observed in
groups 2, 1, and 3, respectively, is maintained when
rates were corrected for patient weight (ie, mg/h/
kg), indicating that variation in patient weight be-
tween groups was not responsible. Therapeutic drug
monitoring using the test dose was not reliable
when Bu was given over a set infusion time, because
Bu Cl of the test dose was significantly higher than
that of the treatment dose (Figure 1, bar graphs,
groups 1 and 2). However, when both the test andose Trials
Treatment Dose
Dose
Infusion Rate
g mg/h mg/h/kg
0.85) 240 (170-320) 80 (56-107) 0.97 (0.73-1.13)
0.35) 250 (170-300) 79 (49-120) 0.98 (0.77-1.27)
1.91) 220 (134-340) 76 (58-103) 0.99 (0.5-1.92)
r2 = 0.74
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Figure 2. (A) Correlation of Bu day 25 AUC predicted by the test
dosewith the confirmed day25 treatment dose AUC. In patients under-
going fixed rate of Bu infusion without dose adjustment, AUC25 was
predicted by the test dose PK analyses on day 27 and later confirmed
based on the actual day 25 analyses. Points in dashed boundary repre-
sent patients dose adjusted on day 23 based on AUC25. (B) Accuracy
of AUC25 predicted by test dose, represented by margins of error.
298 Biol Blood Marrow Transplant 18:295-301, 2012S. B. Kangarloo et al.treatment doses were administered at the same IR, the
clearance of the drug between the 2 dosing days was
equivalent (Figure 1, bar graphs, group 3).
In the group of patients monitored by the fixed IR
test and treatment dose protocol, the ratio of Treat-
ment Dose/Test Dose was 4, equal to the Treatment
AUC/Test AUC ratio, thereby allowing exposure pre-
dictions and dose adjustments based on the test dose
PK analysis. Essentially, this was only possible when
the clearances between the test and treatment days
were equivalent, because it was only then that the
dose ratios were equal to AUC ratios. We analyzed
the influence of seizure prophylaxis medication on Cl
of Bu among the fixed IR group of patients. The first
83 patients were given phenytoin, both during the
test and treatment days of Bu and respectively showed
mean Bu Cl of 3.2 mL/min/kg and 3.3 mL/min/kg
(nonsignificant difference). The remaining 183 pa-
tients received lorazepam, and the mean Bu Cl during
both test and treatment days were 2.8 mL/min/kg.
There was a high linear correlation (r2 5 0.74 be-
tween the predicted and confirmed exposures of all
266 patients who received the test and treatment doses
of Bu at the same IR (Figure 2A). Furthermore, we ex-
amined these data in terms of the accuracy of test
dose predictions to illustrate the margins of error
(Figure 2B). Mean absolute error for the test dose pre-
dicted AUC25 was 6.3% (95% CI; 5.7% to 6.9%),
with 98% of the predictions, involving all but 4 pa-
tients, within6 20% error and 80% of the predictions
within6 10%. Review of clinical status and treatment
of these 4 patients indicated that changes in medica-
tion or hepatic function might have contributed to
these errors. In 2 patients, changes in phenytoin doses
were required; in the third patient, liver function was0.0
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Figure 1. Comparison of i.v. Bu Cl in 3 different test dose trials. Group
1. N5 34, 12-mg test doses infused over 20 minutes, with 3-hour treat-
ment dose infusions. Group 2.N5 11, 0.8-mg/kg test doses, with 3-hour
test and treatment dose infusions. Group 3. N 5 266, 0.8 mg/kg test
doses, 80-mg/h test, and treatment dose fixed-rate infusions. All treat-
ment doses were 3.2 mg/kg, every 24 hours. P values were determined
when comparing the test clearance to the treatment clearance in each
paired group. Mean6 SEM indicated. **Highly significant difference.recovering; and for the fourth patient, the IR of test
and treatment doses differed. A total of 6 patients
had a dose adjustment on day 23 based on day 25
levels .5800 mM$min, and clinical decisions were
made to reduce the dose on that day.
We reduced the dose in 24 patients where the fixed
IR test dose predicted an exposure .5500 mM$min
(Figure 3A). Themean dose reductionwas 19% (range:
9% to 39%). After dose reductions, the mean con-
firmed AUC25 was 4885 mM$min, with % CV of
10% and range of exposures between 4059 mM.min
to 5844 mM$min. Hence, in all of these patients, we
kept Bu exposure below our upper AUC limit of 6000
mM$min. In fact, based on the fixed IR test dose mon-
itoring, in the 290 patients (Figures 2A and 3A com-
bined), only 1 patient exceeded our critical exposure
level of 6000 mM$min for the first treatment dose of
Bu. This patient’s Bu dose was reduced on day 23.
We evaluated the accuracy of our dose adjustments
based on themargin of error away from the desired tar-
get exposure (Figure 3B). All of the adjustments were
within 20% of the desired exposure, and 60% of the
adjustments were within 10% of the target. Mean ab-
solute error was 8% (95% CI: 6.3% to 10.5%).
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Figure 3. (A) Patients having dose adjustments based on test dose pre-
dictions. Initial predicted AUC represents AUC25 predicted by test
dose before the dose adjustment. Adjusted confirmed AUC represents
actual AUC25 after dose reduction. (B) Accuracy of test dose adjust-
ments represented by margins of error. The graph shows the AUC25
after dose adjustment plotted against the error expressed as a percent-
age of the intended target AUC. The intended target AUC in 21 patients
was 5000 mM$min and in 3 patients it was 5500 mM$min.
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While developing a test dose strategy for once-
daily i.v. Bu, we found that accurate prediction of the
therapeutic doses can be achieved if the test and treat-
ment doses are given at the same rate. Because drug
clearance is expressed in units of volume per unit
time, the physical interpretation of clearance is the vol-
ume of fluid presented to the eliminating organ (the
extractor organ, eg, liver or kidney) that is completely
cleared of drug per unit time [18]. For Bu, a drug with
linear monophasic kinetics, the rate of change of drug
in the body 5 IR – Cl  C (where C is drug plasma
concentration). Under steady state conditions: Cl 5
IR/Css (where Css is drug plasma concentration at
steady state); hence, as IR increases, Cl will increase
[19]. However, with once-daily i.v. Bu and typical 3-
hour treatment dose infusion times, steady state is
not achieved and therefore the previously described
steady-state relationship between IR and Cl does not
apply. This is because for C to approach steady-state
levels, infusion lengths of 3 to 4 half-lives are required.
Given that the mean plasma elimination half-life for
Bu is about 3 hours, it would take approximately 12
hours of drug infusion to achieve Css, clearly notpossible with the relatively short infusion times of ev-
ery 24-hour i.v. Bu in current protocols.
We observed alterations in Bu clearance dependent
on rate of infusion among our different trials comparing
test dose to treatment dose. Bu clearance appeared to be
IR dependent, that is, rate dependency was observed at
least for low (\45 mg/h) IRs when test and treatment
rates differed by at least 2-fold. This is an IR-
dependent nonlinear behavior for Bu previously not
described to our knowledge. Plausibly a rate-limiting
process in the liver may be invoked to account for the
change in clearance dependent on the rate of drug infu-
sion. This phenomenon might be attributed to the low
hepatic extraction behavior of Bu. Such behavior is con-
sistent with the observed increase in Bu’s Cl in combina-
tion with phenytoin, a drug that induces CYP3A4
enzymes involved in the metabolic pathway of Bu
[20-23]. We also observed higher Bu Cl in the presence
of phenytoin compared with lorazepam. Conceivably,
there is a threshold of IR above 45 mg/h, above which
clearance of test and treatment doses would be similar
even if they were infused at different rates. We do not
have sufficient data to answer this question.
Previous reports have shown that nonrelapse mor-
tality increases significantly when daily exposure to
once-daily Bu exceeds 6000 mM$min [14]. Our study
confirms that a test dose may help to avoid such expo-
sures by appropriate dose adjustment, necessary in
about 10% of patients. Targeting a mean daily expo-
sure of 5000 mM$min over 4 days will usually give
a safe margin of error if the aim is simply to avoid levels
.6000 mM$min. It may be important to remember
that allowance needs to be made for the contribution
of the test dose itself to the total exposure.
Hitherto, we have simply used the test dose to
maintain total daily exposures\6000 mM$min. This
strategy will clearly allow targeting exposure to any
chosen level. Thus, for example, we have preliminary
evidence that, when total body irradiation is included
in the regimen for acute myelogenous leukemia, daily
exposures below 4320 mM$min may be optimal [24].
Currently, we have no evidence that exposures
\6000 mM$min but otherwise within the range seen
with current dosing significantly affect outcomes
when totalbody irradiation is not used.
Other studies of daily i.v. Bu have supported the
practice of using a test dose for daily i.v. Bu. Beri
et al. [17] showed a close correlation between the
AUC of a test dose and that of a first treatment dose
given 2 weeks later to 17 patients. The ratio of IRs of
test and treatment doses was 0.8 to 1.06, less than
the range of 2- to 4-fold in our first 2 cohorts. Tse
et al. [16] found that a test dose 5 days before the first
treatment dose improved the accuracy of prediction
for a pediatric population, but that 6 of 18 patients
\4 years old had treatment dose AUCs outside the tar-
get range of 3200 to 4800 mM$min. The accuracy of
300 Biol Blood Marrow Transplant 18:295-301, 2012S. B. Kangarloo et al.prediction was somewhat better in older children, with
84%within the same range. The information provided
suggests that the IRs of test and treatment doses dif-
fered by at least 2-fold.
Although it is possible to make dose, adjustments
based on the PK of the first treatment dose, it is diffi-
cult to do so before the third dose, even with an in-
house PK service [15]. Giving the test dose a week or
2 before treatment may allow more time for reporting
from outside laboratories. However, this may be less
convenient for patients, some of whom travel long dis-
tances to the transplantation center. It may also make
errors because of metabolic changes more likely.
Careful scrutiny of occasions where the correlation
between test and treatment doses was poor has allowed
us to identify and emphasize certain pitfalls in PK
monitoring. Some of these deviations are attributable
to medication changes, for example, withdrawal of
phenytoin if the patient was unable to tolerate it. For
this reason, we now use lorazepam as an anticonvulsant
because it does not interfere with Bu metabolism
[20,25]. Other changes in medications that might
influence Bu metabolism should be recorded, as well
as alterations in liver function. Such events should
raise the level of suspicion that the correlation
between test and treatment doses may not be
accurate. In this case, measurement of the first Bu
treatment AUC may be particularly important.
Close attention should also be paid to the details of
infusion of all Bu doses and of blood sampling. Accuracy
may be improved by ensuring that the same infusion
pump is used for both test and treatment doses. Proper
sampling technique, particularly from central lines, and
precise recording of sample times are critical. Although
test doses lower than 0.8 mg/kg could be used, the
dose needs to be sufficient for infusion and sampling to
be timed accurately enough. In adults, a dose of
0.8 mg/kg is usually infused over 30 to 60 minutes if
a rate of 80 mg/h is used. If the common treatment
schedule of 0.8 mg/kg every 6 hours is used, then a test
dose of 0.8 mg/kg is likely to be given over the same
time and the caution about IR may not be necessary.
Although the PK behavior of i.v. Bu is much more
predictable and consistent than that of the oral form,
there remains a 3- to 4-fold variation in exposure expe-
rienced by different patients if a fixed dose is used. There
is evidence that therapeutic drugmonitoring is still valu-
able, particularly if the agent is given in myeloablative
regimens. The use of a reliable test dose strategy as de-
scribed here may help to improve the safety of regimens
containing i.v. Bu without sacrificing their efficacy.ACKNOWLEDGMENTS
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